编者按：2025年1月2日，国家药品监督管理局（NMPA）官网显示[1]，吉利德（上海）医药科技有限公司的Lenacapavir（LEN，来那帕韦钠片和来那帕韦钠注射液）正式获批，用于与其他抗反转录病毒（ARV）药物联合使用,治疗当前方案无法达到病毒 ...

This manuscript provides valuable information about the genesis of CPSF6 condensates due to HIV-1 infection. However, the evidence is incomplete as it is missing more functional assays. Furthermore, ...

The US drug administration has approved the use of the medication as an injection for use against the multidrug resistant ...

Wesley Sundquist’s lab laid foundation for development of a highly effective, long-lasting preventive measure against HIV.

Antiretroviral therapy effectively suppresses HIV viral loads to undetectable levels but cannot eliminate the integration of viral DNA into the host cell genome. A novel class of HIV-1 antivirals that ...

Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...

As recognized by Science, the development of lenacapavir's has come through many years of research into the structure and ...

The drug, named lenacapavir, targets the structure and function of HIV's capsid protein. It protects people for 6 months with each shot. Unlike mainstay HIV drugs that disrupt viral enzymes by ...

The award also recognizes related work surrounding gaining a new understanding of the structure and function of HIV’s capsid protein. Despite decades of advancements, HIV continues to infect ...

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets ...

This year we saw more examples of the destructive effort to undermine abortion as a health service. But overreach into health practices was not limited to abortion care.